Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of CF102 in NAFLD/NASH
MOH_2017-10-28_000341Phase 2Completed
- Sponsor
- Can-Fite BioPharma Ltd.
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of namodenoson in metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) (3 arms), sponsored by Can-Fite BioPharma Ltd. Primary endpoint: Not reported in registry entry. Started Mar 2017; status: completed.
02
Drugs
namodenoson
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on MOH_2017-10-28_000341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-10-28_000341.